Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 pos MSH2 E226* MSH2 E580* MSH2 A913fs MSH2 neg MSH6 R361H MSH6 neg |
| Therapy | Durvalumab + MEDI0680 |
| Indication/Tumor Type | renal pelvis transitional cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 pos MSH2 E226* MSH2 E580* MSH2 A913fs MSH2 neg MSH6 R361H MSH6 neg | renal pelvis transitional cell carcinoma | predicted - sensitive | Durvalumab + MEDI0680 | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Imfinzi (durvalumab) and MEDI0680 (AMP-514) obtained through a Phase I trial resulted in a complete response ongoing for at least 11 months in a patient with metastatic MSH2 and MSH6-negative, CD274 (PD-L1)-positive urothelial carcinoma of the renal pelvis harboring MSH2 A913fs, E226*, and E580*, and MSH6 R361H (PMID: 26674132; NCT02118337). | 26674132 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26674132) | Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. | Full reference... |